Recent

% | $
Quotes you view appear here for quick access.

Sanofi Message Board

biotech_invest 156 posts  |  Last Activity: 14 hours ago Member since: Mar 5, 1998
  • Reply to

    TANZI April 13, 8 PM talk

    by alzwatch Apr 11, 2016 1:51 PM
    biotech_invest biotech_invest Apr 12, 2016 11:36 AM Flag

    you can learn here (wwwDOTinnocentiveDOTcom/ar/challenge/topSolvers - you can start from 2013) how I already helped to many pharma companies like Pfizer, Cleveland Clinics, Boehringer Ingelheim etc to find at least the directions how to cure some incurable diseases.
    And if some Big Pharma will ask how to cure AD (or at least in which direction they should dig) and they will pay good award money for the solution I'm always ready to help.

  • Reply to

    TANZI April 13, 8 PM talk

    by alzwatch Apr 11, 2016 1:51 PM
    biotech_invest biotech_invest Apr 12, 2016 10:53 AM Flag

    I hope they didn't forget to invited Prof Wischik :-) Did they?
    It will be a big fun if Wischik AD drug met primary goals in Ph3 AD trial while all anti-amyloid drugs including BACE inhibitors fail to show any improvement in slow down of AD cognition decline. We will see the results of TauRx before July i.e. very soon.
    It's time to short 2 biotech scams AXON and AVXL: TauRx success will crash their stocks in one day.
    LLY AD drug is also very weak. So, if LMTX® met primary goals and significantly change ADAS-cog11 during 78 weeks of treatment investors will sell LLY shares.
    PRAN is already out of AD game but smart investors remember that in Ph3 HD trial they will again test PBT2 which is a fake drug.

    Sentiment: Strong Sell

  • Reply to

    TANZI April 13, 8 PM talk

    by alzwatch Apr 11, 2016 1:51 PM
    biotech_invest biotech_invest Apr 12, 2016 8:50 AM Flag

    Really?! You should go to brain scanner and see what is going on in your stupid brains :-) May be you already have some plaques and tangles :-)
    Well, just listen Tanzi and continue sing panegyrics to his genius "metal theory of AD" and AD drug PBT2. BTW you can order PBT2 and start eat it each day. May be your brain will not deteriorate so quickly :-) But it's very unlikely :-)

    Sentiment: Strong Sell

  • Reply to

    TANZI April 13, 8 PM talk

    by alzwatch Apr 11, 2016 1:51 PM
    biotech_invest biotech_invest Apr 12, 2016 8:19 AM Flag

    Blah blah blah.... LOL! You are nominated as a most active Tanzi as...kisser :-)
    When you and other Tanzi as...kissers start to list all Tanzi achievements like "he is one of the ten most cited researchers in AD" I just want ask very simple question: Did his so-called "metal theory of AD" or those published "co-authored over 475 research articles" bring us AD drug? Cure at least one AD patient? The answer is also very simple: NO. So, I don't care about this BS. Just show me real achievement of Tanzi! If we don't have AD drug based on Tanzi "metal theory of AD" for me "he isn't wearing anything at all".
    If he actually solved the puzzle of AD etiology and his drug really works why AD patients continue to die? Why I should care about his BS articles that he is publishing only for one purpose - to get more money in his retirement saving. He become on those old farters that only slow down a progress in AD research by desperate pushing their stupid theories and suppressing all other theories that contradict with them.
    Once again, if Tanzi couldn't discover AD cure for 30 years he will never find it. With aging and especially after 60 his brain is not become brighter and stronger. It's is known that mental abilities start declining already after 40:
    "To be able to recall an event or new information, the brain must register the information, store it, and then retrieve it when needed. The ability to recall new information, such as reading material, peaks early and gradually becomes more challenging after age 40, particularly for visual material. Studies show that by age 70 the amount of information recalled 30 minutes after hearing a story once is about 75 percent of the amount remembered by an 18-year old"
    So, so you can continue as..kissing process of old farter Tanzi during next 5-10 years :-) Then he will retire and get happy life (especially if some other scientists will discover AD drug and he will know that his potential AD will be well treated).

    Sentiment: Strong Sell

  • Reply to

    The Burning Question - WHY?

    by copper725 Apr 11, 2016 6:30 AM
    biotech_invest biotech_invest Apr 11, 2016 2:45 PM Flag

    can't understand you stupid gibberish suggestions :-) PBS was always for me Phosphate-buffered saline (abbreviated PBS) :-)
    NOVA is Northern Virginia Community College :-)
    Any way I'm not going to contact anybody about anything :-)

    Sentiment: Strong Sell

  • Reply to

    TANZI April 13, 8 PM talk

    by alzwatch Apr 11, 2016 1:51 PM
    biotech_invest biotech_invest Apr 11, 2016 2:32 PM Flag

    Will this buffoon again talk about his ingenious "metal theory of AD"? Tanzi is 60 years old now and if he couldn't discover AD drug during a time when his brain was young he will never find it. At least he was smart enough to fool PRAN investors and make some money for happy retirement life :-)

    Sentiment: Strong Sell

  • Reply to

    The Burning Question - WHY?

    by copper725 Apr 11, 2016 6:30 AM
    biotech_invest biotech_invest Apr 11, 2016 2:27 PM Flag

    LOL! some anonymous PRAN poster did so deep conclusions "you are not smart enough" :-) Is it means that you are smarter? Do you have any proof of your smartness?
    Well, I'm also anonymous poster but at least I have 100% proof that I'm smart enough (look here wwwDOTinnocentiveDOTcom/ar/challenge/topSolvers and you will easy find me among InnoCentive Top Solvers for last 3 years i.e. 2013-15. Almost sure in 2016.
    Not enough?
    All biotech companies are challenges for me i.e. I'm cracking their sciences and make a simple conclusions: SCAM or GEM. PRAN is 100% SCAM. So, my advice is simple: make money on PRAN by knowledge that it's SCAM.

    Sentiment: Strong Sell

  • Reply to

    The Burning Question - WHY?

    by copper725 Apr 11, 2016 6:30 AM
    biotech_invest biotech_invest Apr 11, 2016 1:49 PM Flag

    should correct your numbers: in after 1:6 RS price $13.38 becomes almost $80
    Since current pps is $3.39, PRAN holders that bought PRAN at High i.e. $12-13 range lose -96%.
    For holders that bought PRAN at $2.50 (or $15 after !:6 RS price) losses are not so big i.e. -80%.
    Holders that are buying PRAN now for $3.39 and see $1 after FDA reject Complete Response the losses will be just -70%. Not so terrible as -96% or -80% :-)

    Sentiment: Strong Sell

  • Regains Compliance with NASDAQ Continued Listing Requirements only because of 1:6 reverse split :-)

    About Continues to Work Towards FDA Submission:
    "The Company also announced that it continues to focus on its submission to the U.S. Food and Drug Administration to lift the partial clinical hold, which limits the development of PBT2 in the United States. The submission is well advanced, and the Company is committed to ensuring it is comprehensive and puts Prana in the strongest position to continue to develop PBT2 in the U.S. market."
    In my recent post I said:
    "CEO will update them about PCH lift in April 22:
    We have only 3 scenarios: 1) he will say that PRAN already sent Complete Response and just waiting for FDA response during 30 calendar days after submission; 2) if PRAN already sent this Complete Response (for example in the middle of March) they will get FDA feedback in the middle of April - so Prana will release this info just exactly before April 22 and IF this news are positive Kempler will have a strong trump card to attract Big Pharma to Ph3 HD; 3) no real news just again promises that Prana will continue to discuss with FDA how to lift PCH of Ph3 HD.
    "continues to work towards FDA submission" - looks like PRAN holders will have #3 in April 22. It's very unlikely that Big Pharma interest will be catch with such "good news".
    Any way, yahoo must correct PRAM market cap immediately.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Apr 8, 2016 4:16 PM Flag

    GS and others likes to make money on scam :-) QVT is smartest one: made huge money on AXON and now out before AXON crash (GS even never had AXON).
    QVT FINANCIAL LP 12/31/2015 0 (75,000,000) Sold Out

    look at AXON funds/institutions statistics:
    Institutional Ownership 29.48%
    Total Shares Outstanding (millions) 99
    Total Value of Holdings (millions) $371

    Active Positions

    HOLDERS SHARES
    Increased Positions 46 2,881,899
    Decreased Positions 35 78,422,309
    Held Positions 10 (52,078,004)
    Total Institutional Shares 91 29,226,204

    New and Sold Out Positions

    New Positions 19 709,635
    Sold Out Positions 21 76,832,198

    QVT FINANCIAL LP 12/31/2015 0 (75,000,000) Sold Out

  • Question is why numerous funds/institutions believes in AXON scam but they ignore PRAN scam?
    What is AXON AD drug?
    RVT-101 is an orally administered, potent antagonist of the 5HT6 receptor. Blocking the 5HT6 receptor promotes the release of acetylcholine, an essential neurotransmitter needed for normal cognition and function. Together, RVT-101 and donepezil may work to preserve acetylcholine and improve the cognition and function of patients with mild to moderate Alzheimer’s disease.
    We are developing RVT-101 for adjunctive use with donepezil, a drug that inhibits cholinesterase from breaking down acetylcholine. Cholinesterase inhibitors, like donepezil, are the only class of drugs approved by the FDA for the treatment of patients with mild to moderate Alzheimer’s disease.
    It's just a palliative drug that will never cure AD. But this drug can make billion dollars sales per year. But only if TauRx drug fail Ph3 AD trial.

    Top Institutional Holders
    Holder Shares % Out Value* Reported
    Visium Asset Management 5,077,385 5.12 91,545,256 Dec 31, 2015
    RA Capital Management, LLC 5,000,000 5.04 90,150,005 Dec 31, 2015
    Capital Research Global Investors 4,076,827 4.11 73,505,194 Dec 31, 2015
    JANUS CAPITAL MANAGEMENT, LLC 3,370,555 3.40 60,771,110 Dec 31, 2015
    Shaw D.E. & Co., Inc. 1,610,092 1.62 29,029,960 Dec 31, 2015
    FMR, LLC 1,484,670 1.50 26,768,601 Dec 31, 2015
    Franklin Resources, Inc 1,192,179 1.20 21,494,988 Dec 31, 2015
    Price (T.Rowe) Associates Inc 1,010,200 1.02 18,213,907 Dec 31, 2015

    Sentiment: Strong Sell

  • current pps $2.84 is equal to 47 cents before 1:6 reverse split. PRAN holders still have a hope that Prana CEO will update them about PCH lift in April 22.
    Again we have only 3 scenarios: 1) he will say that PRAN already sent Complete Response and just waiting for FDA response during 30 calendar days after submission; 2) if PRAN already sent this Complete Response (for example in the middle of March) they will get FDA feedback in the middle of April - so Prana will release this info just exactly before April 22 and IF this news are positive Kempler will have a strong trump card to attract Big Pharma to Ph3 HD; 3) no real news just again promises that Prana will continue to discuss with FDA how to lift PCH of Ph3 HD.
    Also inside of scenario $2 we have the possibility of devastating news for PRAN: FDA is not persuaded by a Complete Response and will not lift PCH for PBT2 250 mg daily without strong data from animal tox studies. It will induces at least -50% drop of current pps i.e. to $1.40 and below in one day. Without active Ph3 HD Prana is practically dead biotech with pps declining to $1 and below before end of 2016.
    What is about upside potential if FDA lift Ph3 with 250 mg daily dosing? May be +100% jump i.e. to $5-6 (or $1 pps before 1:6 RS).

    Sentiment: Strong Sell

  • Reply to

    Vitamin D supplementation and plasma Abeta

    by pivalde Apr 1, 2016 9:02 AM
    biotech_invest biotech_invest Apr 1, 2016 10:36 AM Flag

    well, piv, you got my thumb up for this citation :-) I'll increase my daily 5,000 IU of D to 10,000 IU.
    We don't know exactly what is a role of Abeta in AD etiology but definitely the presence of Abeta plaques in brain is not good for their functioning. If vitamin D increases Abeta clearance from brain it will be better to avoid D deficiency (BTW it's very cheap supplement).

  • it is known that "kappa-opioid receptor agonists inhibit antidiuretic hormone secretion and promote water excretion in humans and experimental animals".
    Read here (wwwDOTbiotechinvestDOTnet/cara.html

    Sentiment: Strong Buy

  • Neurobiol Dis. 2016 Mar;87:19-28. doi: 10.1016/j.nbd.2015.12.006. Epub 2015 Dec 17.
    Caspase-cleaved tau exhibits rapid memory impairment associated with tau oligomers in a transgenic mouse model.
    Kim Y1, Choi H1, Lee W1, Park H1, Kam TI1, Hong SH1, Nah J1, Jung S1, Shin B1, Lee H1, Choi TY2, Choo H1, Kim KK3, Choi SY2, Kayed R4, Jung YK5.
    Author information
    Abstract
    In neurodegenerative diseases like AD, tau forms neurofibrillary tangles, composed of tau protein. In the AD brain, activated caspases cleave tau at the 421th Asp, generating a caspase-cleaved form of tau, TauC3. Although TauC3 is known to assemble rapidly into filaments in vitro, a role of TauC3 in vivo remains unclear. Here, we generated a transgenic mouse expressing human TauC3 using a neuron-specific promoter. In this mouse, we found that human TauC3 was expressed in the hippocampus and cortex. Interestingly, TauC3 mice showed drastic learning and spatial memory deficits and reduced synaptic density at a young age (2-3months). Notably, tau oligomers as well as tau aggregates were found in TauC3 mice showing memory deficits. Further, i.p. or i.c.v. injection with methylene blue or Congo red, inhibitors of tau aggregation in vitro, and i.p. injection with rapamycin significantly reduced the amounts of tau oligomers in the hippocampus, rescued spine density, and attenuated memory impairment in TauC3 mice. Together, these results suggest that TauC3 facilitates early memory impairment in transgenic mice accompanied with tau oligomer formation, providing insight into the role of TauC3 in the AD pathogenesis associated with tau oligomers and a useful AD model to test drug candidates.

  • biotech_invest biotech_invest Mar 31, 2016 11:22 AM Flag

    Yahoo still show false PRAN cap $152M. Must be $25.6M i.e. significantly lower than cash level. For how long they will mislead investors? Some of them will finally sue Yahoo if they bought PRAN shares after reverse split and will have huge losses after April 22 when Prana CEO will again issue one more stupid update like "we are continue working with FDA to lift PCH". "Sell in May..." will finally crash PRAN pps below $2 (or 33 cents in old price before RS 1:6).
    BTW, it's interesting what PRAN pumpers will say after April 22 "update"? What will be new "hope date" for Prana adamant holders that are deep under water (even if they bought my shares that I sold at $1.09 with 15% losses)?
    Everybody who shorted PRAN at $3.50 has now +20% gain and will have almost +50% at pps $2 in May.
    Even if PRAN lift PCH for Ph3 HD in late 2016 shorts will not be hurt badly.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Mar 30, 2016 2:24 PM Flag

    3 months and we will know how effective drug that destroy Abeta aggregates in AD neurons.
    TauRx will also measure "Reduction in glucose uptake decline in the temporal lobe on 18F-fluorodeoxyglucose positron emission tomography. [18F]FDG-PET has been shown an
    adequate tool to detect metabolic deterioration in AD patients better than amyloid-PET. It has been proposed as a
    surrogate biomarker to evaluate the effect of disease-modifying drugs in AD with a five times higher power than the
    commonly used neuropsychological scales.

  • biotech_invest biotech_invest Mar 30, 2016 11:20 AM Flag

    come on, enig :-) your question was:
    4) do plaques cause Alzheimers? Will plaque removal reverse Alzheimers? And this question is not answered yet.
    if you answer NO for the first part and prove it 100% you will actually resume AD etiology. But in this case you should discover the real reason that cause AD. For example, you say it's tau tangles and aggregates that release to extracellular space and "infect" healthy neighbor neurons similarly prion mechanisms. Indeed, in case of tauopathies patients have only pathological aggregation of tau protein in their brains and they don't have any amyloid plaques.
    But may be even tau oligomers is not AD reason. What if some unknown factor X induces tau aggregation and make them resistant to proteasome degradation?
    If TauRx drug that destroy tau aggregates fails in Ph3 both amyloid and tau theories of AD will get a strong kick. But don't think that "metal theory of AD' will become basic one. It's just a BS.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Mar 30, 2016 10:44 AM Flag

    Well, I see now that you have absolutely poor imagination i.e. poverty of intellect.
    When people with normal imagination see a combination Noble prize they don't care about misprinting and understand it as Nobel Prize. Because there is no other interpretation possibility. Of course, if you see Shnobel prize may be you never heard of it. So, you are nominated for Shnobel prize as poster with poorest imagination on this MB.
    I'm not surprised any more why you still believe in so-called "metal theory of AD" :-) Only people that have such poverty of intellect continue to believe Tanzi and his cronies.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Mar 29, 2016 10:05 PM Flag

    LOL! Everybody who answer #4 correctly and prove it will get a Noble prize :-) #1-3 are just stupid questions because so-called "metal theory of AD" is just a BS invented by Tanzi and his cronies to get some money for happy life. Tanzi as..kissers like you desperately trying to attract more attention to PRAN scam but all your attempts are laughable :-) PBT2 is just useless metal chelator.
    But it will be interesting to have PBT2 in Ph3 HD. It will repeat the history of Dimebon Ph3 AD trial.

    Sentiment: Strong Sell

SNY
41.26+0.15(+0.36%)May 27 4:02 PMEDT